- A Life study of over 700 people with Long COVID found a significant disruption in blood supply to peripheral tissues. The disruption is caused by microvascular loss and hemodynamic decrease and can lead to hypoxia among other outcomes, the study stated. The author proposed that this disruption was the principal cause of Long COVID.
- Co-investigators Michael Peluso and Wes Ely of the clinical trial on baricitinib, an immune-modulating drug, wrote in a new op-ed in Nature Index that Long COVID may help us solve neurocognitive disorders like Alzheimer’s. “Insights from a new critical mass of patients are proving invaluable,” they wrote.
- CURE-ID, the Food and Drug Administration’s (FDA) survey to identify Long COVID treatments, has reached 500 responses and will now start analyzing results to share with the public. They are still looking for responses — you can fill out the survey here and read our prior coverage for more information about the study.
- Follow Long COVID Weekly for more free research updates each week.
Leave a Reply